ArticleBMC ophthalmology2025
Quantitative infrared meibography for ocular rosacea: lower eyelid meibomian gland loss as a diagnostic marker.
Article in BMC ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo quantitatively assess meibomian gland loss (MGL) using infrared meibography in patients with ocular rosacea and to evaluate its diagnostic performance and relationship with ocular surface parameters.
methodsThirty eyes from 30 patients with ocular rosacea and 34 eyes from 34 controls were analyzed. The Ocular Surface Disease Index (OSDI), Schirmer I test (without anesthesia), Oxford staining, and non-invasive tear break-up time (NITBUT) were recorded. Infrared meibography (Sirius system) quantified MGL in both upper and lower eyelids. Receiver operating characteristic (ROC) curve and logistic regression analyses were performed.
resultsMeibomian gland loss was significantly higher in both upper (31.4 ± 13.8% vs. 20.0 ± 7.3%) and lower (46.0 ± 12.5% vs. 18.4 ± 9.6%) eyelids of patients compared with controls (both p < 0.001). ROC analysis showed excellent diagnostic accuracy for lower-lid MGL (AUC = 0.97, 95% CI: 0.93–1.00; p < 0.001) with an optimal cut-off of 30.2%, yielding 100% sensitivity and 91% specificity, whereas upper-lid MGL showed moderate accuracy (AUC = 0.77, 95% CI: 0.62–0.91). Lower-lid MGL showed a strong correlation with NITBUT (r = − 0.63) and modest but significant correlations with OSDI (r = 0.32) and Oxford staining (r = 0.29; all p < 0.05).
conclusionsOcular rosacea is associated with marked meibomian gland dropout in both eyelids, with the lower lid showing superior diagnostic performance. Quantitative infrared meibography provides an objective and practical tool for assessing gland involvement in ocular rosacea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.